Your shopping cart is currently empty

Reticuline is an anti-inflammatory and antihypertensive natural product that reduces JAK2/STAT3 and NF-κB phosphorylation levels, inhibits TNF-α and IL-6 mRNA expression, thereby alleviating oedema in rats.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | $1,390 | Inquiry | Inquiry |
| Description | Reticuline is an anti-inflammatory and antihypertensive natural product that reduces JAK2/STAT3 and NF-κB phosphorylation levels, inhibits TNF-α and IL-6 mRNA expression, thereby alleviating oedema in rats. |
| In vitro | In intact endothelium aortic rings, reticuline (3 μM-1.5 mM) concentration-dependently inhibited phenylephrine- and KCl (80 mM and 30 mM)-induced contractions, with IC50 values of 40±10, 240±40, and 300±40 μM, respectively [2]. After endothelium removal, the inhibitory effect of reticuline on phenylephrine-induced contraction was significantly attenuated, with an IC50 value of 250±70 μM [2]. In the presence of L-NAME (100 or 300 μM) or atropine (1 μM), the vasorelaxant effect of reticuline was also markedly reduced [2]. Reticuline further suppressed CaCl2-induced contraction and calcium transients triggered by the release of intracellular calcium stores sensitive to depolarizing agents such as phenylephrine, but did not affect caffeine-sensitive calcium stores [2]. |
| In vivo | Reticuline (5, 10, and 20 mg/kg, intravenous injection) induced significant hypotensive responses in normotensive Wistar rats, accompanied by increased heart rate. After pretreatment with L-NAME or atropine, the hypotensive effect and tachycardia caused by reticuline were markedly attenuated or even completely abolished [2]. |
| Molecular Weight | 329.39 |
| Formula | C19H23NO4 |
| Cas No. | 485-19-8 |
| Smiles | C([C@H]1C=2C(=CC(OC)=C(O)C2)CCN1C)C3=CC(O)=C(OC)C=C3 |
| Relative Density. | 1.217g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (242.87 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (10.02 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.